Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 4, 2004 - Issue 3
Submit an article Journal homepage
53
Views
4
CrossRef citations to date
0
Altmetric
Review

Novel peptide-based HIV-1 immunotherapy

Maja A Sommerfelt Bionor Immuno AS, Strømdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. [email protected]
,
Jørgen Nyhus Bionor Immuno AS, Strømdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. [email protected]
&
Birger Sørensen Bionor Immuno AS, Strømdaljordet 4, PO Box 1823 Gulset, NO-3703 Skien, Norway. [email protected]
Pages 349-361 | Published online: 03 Mar 2005

Bibliography

  • REDFIELD RR, BIRX DL, KETTER N et al.: A Phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. N Engl. Med (1991) 324:1677–1684.
  • LINDENBURG CEA, STOLTE I, LANGENDAM MW et al.: Long-term follow up: no effect of therapeutic vaccination with HIV-1 p17/p24:Ty virus-like particles on HIV-1 disease progression. Vaccine (2002) 20:2343–2347.
  • ROSENBURG ES, ALTFIELD M, POON SH et al: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407:523–526.
  • ROBBINS GK, ADDO MM, TROUNG H et al.: Augmentation of HIV-1-specific Th cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS (2003) 17 (8):1121–1126.
  • VITTINGHOFF E, SCHEER S, O'MALLEY P et al.: Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. j. Infect. Dis. (1999) 179:717–720.
  • CARR A, COOPER DA: Adverse effects of antiretroviral therapy. Lancet (2000) 356:1423–1430.
  • FANTONI M, DEL BORGO C, AUTORE C: Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. AIDS (2003) 17\(Suppl. 1):S162–S169.
  • WILSON JW: Update on antiretroviral drug resistance testing: combining laboratory technology with patient care. AIDS Read. (2003) 13(1):25–30, 35–8.
  • APPAY V, NIXON DF, DONAHOE SM et al.: HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function.' Exp. Med. (2000) 192 (1):63–75.
  • WILSON JDK, IMAMI N, WATKINS A et al.: Loss of CD4+ T cell proliferative ability but not loss of human immunodeficiency virus specificity equates with progression to disease. Infect. Dis. (2000) 182:792–798.
  • CHAMPAGNE P, OGG GS, KING AS et al.: Skewed maturation of memory HIV- specific CD8 T lymphocytes. Nature (2001) 410(6824):106–111.
  • ALTFELD M, ALLEN TM, YU XG et al:HIV-1 superinfection despite broad CD8+ T cell responses containing replication of the primary virus. Nature (2002) 420:434–439.
  • KLEIN MR, VAN BAALEN CA, HOLWERDA AM et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. Exp. Med. (1995) 181:1365–1372.
  • RIVIERE Y, MCCHESNEY MB, PORROT F et al.: Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res. Hum. Removiruses (1995) 11:903–907.
  • OGG GS, JIN X, BONHOEFFER S et al:Quantitation of HIV-specific CTL and plasma load of viral RNA. Science (1998) 279:2013–2106.
  • OGG GS, KOSTENSE S, KLEIN MR et al.: Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with diseases progression. Virol (1999) 73:9153–9160.
  • PONTESILLI O, KLEIN MR, KERKHOF-GARDE SR et al: Longitudinal analysis of human immunodeficiency virus type- lspecific cytotoxic T lymphocyte response: a predominant gag-specific response is associated with nonprogressive infection. Infect. Dis. (1998) 178:1008–1018.
  • KAUL R, DONG T, PLUMMER FA et al.:CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J. Clin. Invest. (2001) 107:1303–1310.
  • KAUL R, PLUMMER FA, KIMANI J et al.: HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1 resistant prostitutes in Nairobi. Immunol (2000) 164: 1602-1611.
  • SHEDLOCK DJ, SHEN H: Requirement for CD4 T cell help in generating functional CD8 T-cell memory. Science (2003) 300:337–339.
  • SUN JC, BEVAN MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (2003) 300:339–342.
  • LAMBERT JS, REDFIELD RR, TRAMONT EC: Therapeutic human immunodeficiency virus vaccines: concept, current status and future directions. In: Antiretroviral Therapy De Clercq EDA (Ed.), ASM Press, Washington DC (2001):219–242.
  • MOSS RB, GIERMAKOWSKA WK, SAVARY JR et al.: A primer on HIV type-1 specific immune function and RemuneTm. AIDS Res. Hum. Removiruses (1998) 14\(Suppl. 2):5167–5175.
  • CARCELAIN G, DEBRE., AUTRAN B: Reconstitution of CD4+ T lymphocytes in HIV-infected individuals following antiretroviral therapy. Cum Opin. Immunol (2001) 13:483–488.
  • LANGE CG, LEDERMAN MM: Immune reconstitution with antiretroviral therapies in chronic HIV-1 infection. I Antimicrob. Chemother. (2003) 51 (1):1–4.
  • WU Y, MARSH JW: Selective transcription and modulation of resting T-cell activity by preintegrated HIV. Science (2001) 293:1503–1506.
  • HERMANKOVA M, SILICIANO JD, ZHOU Y et al.: Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes M vivo.' Virol (2003) 77(13):7383–7392.
  • DEEKS SG, WRIN T, LIEGLER T et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viraemia. N Engl. Med. (2001) 344:472–480.
  • MILLER V: Structured treatment interruptions in antiretroviral management of HIV-1. Cum Opin. Infect. Dis. (2001) 14:29–37.
  • MARTINEZ-PICADO J, MORALES-LOPETE GI K, WRIN T et al.: Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS (2002) 16:895–899.
  • LISZIEWICZ J, LORI F: Structured treatment interruptions in HIV/AIDS therapy. Microb. Infect. (2002) 4:207–214.
  • LORI F, FOLI A, LISZIEWICS J: Structured treatment interruptions as a potential alternative therapeutic regimen for HIV-infected patients: a review of recent clinical data and future prospects. Antimicrob. Chem. (2002) 50:155–160.
  • ARMBRUSTER C, STIEGLER GM, VCELAR BA et al.: A Phase I trial with two human monoclonal antibodies (hMab 2F5, 2G12) against HIV-1. AIDS (2002) 16(2):227–233.
  • FERRANTELLI F, RUPRECHT PM: Neutralising monoclonal antibodies against HIV - back in the major leagues? Carr: Opin. Immunol (2002) 14:495–502.
  • RUPRECT PM, FERRANTELLI F, KITABWALLA M, XU W, MCCLURE HM: Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine (2003) 21:3370–3373.
  • RHODES T, WARGO H, HU W-S: High rates of human immunodeficiency virus type 1 recombination: near-random segregation markers one kilobase apart in one round of viral replication. .1 Viral (2003) 77(20):11193–11200.
  • MALIM M, EMERMAN M: HIV-1 sequence variation: drift, shift, and attenuation. Cell (2001) 104(4):469–472.
  • WEI X, DECKER JM, WANG S et al.: Antibody neutralisation and escape by HIV-1. Nature (2003) 422(6929):307–312.
  • •Discusses the concept of a glycan shield and how this promotes immune escape.
  • BAROUCH DH, KUNSTMAN J, KURODA MJ et al.: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature (2002) 415:335–339.
  • PIERSON T, MCARTHUR J, SILICIANO RF: Reservoirs for HIV: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Ann. Rev binnunol. (2000) 18:663–708.
  • •An in-depth overview of HIV reservoirs.
  • SAKSENA NK, POTTER SJ: Reservoirs of HIV-1 M vivo: implications for antiretroviral therapy. AIDS Rev (2003) 5(1):3–18.
  • KLEIN J, SATO A: The HLA System I. N Engl. J. Med. (2001) 343:702–709.
  • •An in-depth overview of the HLA system, genes, structure and function.
  • KLEIN J, SATO A: The HLA System II. N Engl. J. Med. (2001) 343:782–786.
  • TOMIYAMA H, AKARI H, ADACHI A, TAKIGUCHI M: Different effects of Nef-mediated class I downregulation on human immunodeficiency virus type 1-specific CD8+ T-cell cytolytic activity and cytokine production. J. Virol (2002) 76:7535–7543.
  • KASPER MR, COLLINS KL: Nef-mediated disruption of HLA-A2 transport to the cell surface inT-cells. Virol. (2003) 77:3041–3049.
  • YANG OO, NGUYEN PT, KALAMS SA et al.: Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. (2002) 76:1626–1631.
  • COHEN GB, GANDHI RT, DAVIS DM et al.: The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 10(6):661–671.
  • STUMPTNER-CUVELETTE P, MORCHOISNE S, DUGAST M et al: HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl Acad. Sci. USA (2001) 98(21):12144–12149.
  • DOUEK DC, BRENCHLEY JM, BETTS MR et al.: HIV preferentially infects HIV-specific CD4+ T-cells. Nature (2002) 417:95–98.
  • FLAMAND L, CROWLEY RW, LUSSO P, COLOMBINI-HATCH S, MARGOLIS DM, GALLO RC: Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: Implications for HIV pathogenesis. Proc. Natl Acad. Sci. USA (1998) 95:3111–3116.
  • ROSS RW, WRIGHT ME, TAVEL JA: Ongoing trials of immune-based therapies for HIV-1 infection in adults. Expert Opin. Biol. Titer: (2001) 1(3):413–424.
  • BERZOFSKY JA: Approaches and issues inthe development of vaccines against HIV. I Acquic Immune Defic. Synth: (1991) 4:451–459.
  • BERZOFSKY JA, BERKOWER IJ: Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994–1995. AIDS(1995) 9(Suppl. A):5143–5157.
  • CHOPPIN J, COHEN W, BIANCO A et al.: Characteristics of HIV-1 Nef regions containing multiple CD8+ T cell epitopes: wealth of HLA-binding motifs and sensitivity to proteasome degradation. .1. Immunol (2001) 166(10):6164–6169.
  • KESSLER JH, BEEKMAN NJ, BRES-VLOEMANS SA et al.: Efficient identification of novel HLA-A 0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis..! Exp. Med. (2001) 193(1):73–88.
  • •One of the first papers discussing antigen processing within proteasomes.
  • DE GROOT AS, JESDAL B, MARTIN W et al.: Mapping cross clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine (2003) 21:4486–4504.
  • BERZOFSKY JA, AHLERS JD, BELYAKOV M: Strategies for designing and optimizing new generation vaccines. Nat. Rev Immunol. (2001) 1(3):209–219.
  • •An extensive review on modern vaccine strategies.
  • TSOMIDES TJ, WALKER BD, EISEN HN: An optimal viral peptide recognised by CD8+T cells binds very tightly to the restricting class I major histocompatibility complex protein on intact cells but not to the purified class I protein. Proc. Natl. Acad. Sci. USA (1991) 88:11276–11280.
  • HUMPHREYS RE, ADAMS S, KOLDZIC G, NEDELESCU E, VON HOFE E, XU M: Increasing the potency of MHC class II-presented epitopes by linkage to Li-Key peptide. Vaccine(2000) 18:2693–2697.
  • KALLINTERIS NL, LU X, WU S et al: Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV. Vaccine (2003) 21:4128–4132.
  • MOORE CB, JOHN M, JAMES IR, CHRISTIANSEN FT, WITT CS, MALALL SA: Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science (2002) 296:1439–1443.
  • KIM DT, MITCHELL DJ, BROCKSTEDT DG et al: Introduction of soluble proteins into MHC class I pathway by conjugation to an HIV Tat peptide. Immunol. (1997) 159:1666–1668.
  • NYHUS J, SOMMERFELT MA, SORENSEN B: Peptide from Tat basic domain shows striking similarity to a region of the human T-cell transcription factor (TCF)-1. AIDS Res. Hum. Retroviruses (2003) 19:345–346.
  • LIVINGSTON B, CRIMI C, NEWMAN M et al.: A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. Immunol. (2002) 168:5499–5506.
  • ANDRIEU M, DESOUTTER J-F, LOING E et al: Two human immunodeficiency virus vaccinal lipopeptides follow different cross-presentation pathways in human dendritic cells." Virol (2003) 77:1564–1570.
  • HICKLING JK: Measuring human T-lymphocyte function. Expert Rev Mol. Merl (1998) 1:1–20.
  • NIETFELD W, BAUER M, FEVRIER M et al.: Sequence constraints and recognition by CTL of an HLA-B27 restricted HIV Gag epitope.j Immunol (1995) 154:2188–2197.
  • MANNERING SI, PURCELL AW, HONEYMAN MC, MCCLUSKY J, HARRISON L: Human T-cells recognise N-terminally Fmoc-modified peptide. Vaccine (2003) 21:3638–3646.
  • PINTO LA, BERZOFSKY JA, FOWKE KR et al.: HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (1999) 13(15):2003–2012.
  • GORSE GJ, KEEFER MC, BELSHE RB et al.: A dose-ranging study of a prototype synthetic HIV-1MN V3 branched chain peptide vaccine. J. Infect. Dis. (1996) 173:330–339.
  • LAMBERT JS, KEEFER M, MULLIGAN M et al.: Phase I safety and immunogenicity trial of UBI° microparticulate monovalent HIV-1MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine (2001) 19:3033–3042.
  • PIALOUX GH, GAHERY-SEGARD S, SERMET S et al.: Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS (2001) 15:1239–1249.
  • GAHERY-SEGARD HG, PIALOUX B, CHARMETEAU S et al.: Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency type 1 lipopeptide vaccine. J. Virol. (2000) 74:1694–1703.
  • GAHERY-SEGARD HG, PIALOUX G, FIGEUIREDO S et al.: Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterisation of CD8+-T-cells epitopes recognised. J. Virol (2003) 77(20):11220–11231.
  • VELJKOVIC V, MOLLER S, KOHLER H: AIDSVAX results: an important open question. Vaccine (2003) 21:3528–3529.
  • BANCHEREAU J, STEINMAN RM: Dendritic cells and the control of immunity. Nature (1998) 392:245–252.
  • •A discussion of the potential of dendritic cells as a target for immunisation.
  • HEATH WR, CARB ONE FR: Cross presentation in viral immunity and self tolerance. Nat. Rev Immunol. (2001) 1:126–135.
  • •A generalised overview of cross-presentation.
  • ASJO B, STAVANG H, SORENSEN B, BAKSAAS I, NYHUS J, LANGELAND N: Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res. Hum. Retroviruses(2002) 18(18):1357–1365.
  • CARBONNEIL C, AOUBA A, BUGARD M et al.: Dendritic cells generated in the presence of granulocyte-macrophage colony stimulating factor and IFN-a are potent inducers of HIV-specific CD8 T cells. AIDS (2003) 17: 1731-1740.
  • DHODAPKAR MV, STEINMAN RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivoin humans. Blood (2002) 100:174–177.
  • SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Can: Opin. Immunol (2003) 15:138–147.
  • •A comprehensive review outlining the potential for dendritic cells within cancer immunotherapy.
  • LIU K, IYODA T, SATERNUS M, KIMURA Y, INABA K, STEINMAN RM: Immune tolerance after delivery of dying cells to dendritic cells in situ. J. Exp. Med. (2002) 196(8):1091–1097.
  • RUBINSTEIN A, MIZRACHI Y, PETTOELLO-MANTOVANI M et al: Immunologic responses of HIV-1-infected study subjects to immunisation with a mixture of purified protein derivative-V3 loop peptide conjugates. .1. AIDS (1999) 22:467–476.
  • RUBINSTEIN A, GOLDSTEIN H, PETTEOLLO-MANTOVANI M et al.: Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers. AIDS (1995) 9(3):243–251.
  • AMOSCATO AA, PRENOVITZ DA, LOTZE MT: Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. j kifnunol. (1998) 161:4023–4032.
  • GEEIJTENBEEK TB, KWON DS, TORENSMA R et al: DC-SIGN, a dendritic cell-specific HIV-1 binding protein that enhances trans-infection of T-cells. Cell (2000) 100:587–597.
  • STEINMAN RM, GRANELLI-PIPERNO A, POPE M et al.: The interaction of immunodeficiency viruses with dendritic cells. Can: Top. Microbial Immunol (2003) 276:1–30.
  • STEINMAN RM, POPE M: Exploiting dendritic cells to improve vaccine efficacy. Clin. Invest. (2002) 109(12):1519–1526.
  • CHEN D, ZULEGER C, CHU Q, MAA YF, OSORIO J, PAYNE LG: Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses. AIDS Res. Hum. Retroviruses (2002) 18(10):715–22.
  • KEEFER MC, GRAHAM BS, MCELRATH MJ et al.: Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res. Hum. Retroviruses (1996) 12(8):683–693.
  • KELLEHER AD, EMERY S, CUNNINGHAM P et al: Safety and immunogenicity of UBI HIV-1 MN octameric V3 peptide vaccine administered by subcutaneous injection. AIDS Res. Hum. Retroviruses (1997) 13:29–32.
  • WANG CY, LOONEY DJ, LI ML et at.: Long-term high titre neutralizing activity induced by octameric synthetic HIV-1 antigen. Science (1991) 254(5029):285–288.
  • KAHN JO, STITES DP, SCILLIAN J et al: A Phase I study of HGP-30, a 30 amino acid subunit of the human immunodeficiency virus (HIV) p17 synthetic peptide analogue subunit vaccine in seronegative subjects. AIDS Res. Hum. Retroviruses (1992) 8:1321–1325.
  • BARTLETT JA, WASSERMAN SS, HICKS CB et al.: Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS (1998) 12:1291–1300.
  • EVANS TG, KEEFER MC, WEINHOLD KJ et al.: A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. Infect. Dis. (1999) 180(2):290–298.
  • SALMON-CERON D, EXCLER JL, FINKIELSZTEJN L et al.: Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 MN tm/gag/protease LAI(ALVAC-HIV, vCP205) followed by p24-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res. Hum. Removiruses(1999) 15(7):633–645.
  • CANO CA: The multi-epitope polypeptide approach in HIV-1 vaccine development. Genetic Analysts. Biomolecular Engineering (1999) 15:149–153.
  • SERWOLD T, GONZALEZ F, KIM J, JACOB R, SHASTRI N: ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature (2002) 419:480–483.

Websites

  • http://www.iavi.org International AIDS vaccine initiative.
  • http://www.hvtn.org Human Vaccine Trials Network.
  • http://www.imtech.res.in/raghava/mhcbn/ Comprehensive database of MHC binding and non-binding peptides.
  • http://www.jenner.ac.uldjenpep/ JenPep — Peptide binding database.
  • http://www.uni-tuebingen.de/uni/kxi/ Department of Immunology, University of Tuebingen.
  • http://www.hiv.lanl.gov/content/ immunology/index.html HIV molecular immunology database.
  • http://www.thi.ac.uldimgt/ European Bioinformatics Institute immunogenetics database.
  • http://www.imtech.res.in/raghava/nhlapred/ A neural network-based MHC class I binding peptide prediction server.
  • http://www.imtech.res.in/raghava/ propredl/ A promiscuous MHC class I binding peptide prediction server.
  • http://bimas.dcrtnih.gov/molbio/hla_bind/ HLA peptide binding predictions.
  • http://www.mpfib-berlin.mpg.de/MAPPP/ information.html MHC class I antigenic peptide processing prediction.
  • http://syfpeithi.bmi-heidelberg.com/ Scripts/MHCServer.c111/EpPredict.htm Epitope prediction.
  • http://miLdfci.harvard.edu/Tools/ rankpep.html Rankpep — Prediction of binding peptides to class I and class II MHC molecules.
  • http://bioinfo.md.huji.ac.il/marg/Teppred/ mhc-bind/ PREDEP — MHC class I epitope prediction.
  • http://www.imtech.res.in/raghava/ mmbpred/ MMBPred — Prediction of mutated MHC binders.
  • http://www.imtech.res.in/raghava/propred/ MHC class II binding peptide prediction server.
  • http://www.epipredict.de/index.html EpiPredict website.
  • http://www.sbc.su.se/svmhc/ information.html SVMHC information page.
  • http://www.cbs.dtu.dk/services/NetChop/ NetChop 2.0 prediction server.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.